Drug intelligence / Profile preview

VRC-EBODNA023-00-VP + VRC-MARDNA025-00-VP

Development stage: Unknown
Lead developer: Vaccine Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-EBODNA023-00-VP and VRC-MARDNA025-00-VP are investigational DNA plasmid vaccines developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). These vaccines are designed to prevent Ebola virus disease and Marburg virus disease, respectively. The platform utilizes a DNA plasmid technology with a CMV/R promoter to encode viral glycoprotein antigens. Upon intramuscular administration, host cells take up the plasmids and express the viral proteins, which then stimulate both humoral (antibody) and cellular (T-cell) immune responses against the filoviruses. These candidates have been evaluated in Phase 1 clinical trials, including studies in healthy adults in Uganda, to assess their safety and immunogenicity profile.

Other names: Ebola DNA plasmid vaccineMarburg DNA plasmid vaccineNIAID Ebola/Marburg DNA vaccineVRC Ebola/Marburg DNA vaccine

Targets

PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on VRC-EBODNA023-00-VP + VRC-MARDNA025-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-EBODNA023-00-VP + VRC-MARDNA025-00-VP.

Explore the full profile